Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD)

Jane Street Group LLC acquired a new stake in shares of Affimed (NASDAQ:AFMD) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,240 shares of the biopharmaceutical company’s stock, valued at approximately $44,000. Jane Street Group LLC owned approximately 0.09% of Affimed at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Choreo LLC bought a new stake in shares of Affimed in the 2nd quarter valued at about $54,000. FMR LLC raised its holdings in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares in the last quarter. Intellectus Partners LLC raised its holdings in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on AFMD. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company reduced their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Stifel Nicolaus dropped their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Affimed presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Trading Up 0.9 %

NASDAQ:AFMD opened at $1.08 on Thursday. Affimed has a twelve month low of $1.06 and a twelve month high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The company’s 50 day moving average is $2.15 and its two-hundred day moving average is $3.41.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.